The Mayo ATTR-CM Score Versus Other Diagnostic Scores and Cardiac Biomarkers in Patients with Suspected Cardiac Amyloidosis
European Journal of Heart Failure · 2025
DOI: 10.1002/ejhf.3455 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Giovanni Battista Bonfioli und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of B…. Hauptthemen laut MEDLINE: Cardiomyopathies, Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
Several scores were developed to help the diagnosis of cardiac amyloidosis (CA). The most recent one, being the Mayo transthyretin amyloidosis cardiomyopathy (ATTR-CM) score, was not externally validated. We compared the diagnostic performance of the ATTR-CM score with previous tools (increased wall thickness [IWT] score, AMYLoidosis Index [AMYLI] score, and cardiac biomarkers) in a cohort of patients evaluated for a suspicion of CA. Methods and results We analysed 362 consecutive patients referred to a third-level centre for suspected CA. Overall, 132 (36%) had transthyretin CA (ATTR-CA), and 91 (25%) immunoglobulin light chain CA (AL-CA); CA was excluded in 139 (38%). ATTR-CM score had a good diagnostic performance to distinguish ATTR-CA from AL-CA or no CA, with an area under the curve (AUC) of 0.795 (95% confidence interval [CI] 0.747–0.842, p < 0.001), and ATTR-CA from no CA (AUC 0.822, 95% CI 0.774–0.871, p < 0.001). Results were consistent in both patients with preserved (AUC 0.787, 95% CI 0.726–0.848, p < 0.001), and reduced or mildly reduced ejection fraction (AUC 0.790, 95% CI 0.709–0.871, p < 0.001). The ATTR-CM score showed a better discrimination compared to IWT and AMYLI score to distinguish ATTR-CA from AL-CA or no CA (p = 0.002), but not to distinguish ATTR-CA from no CA (p = 0.270). Diagnostic accuracy was significantly higher for the ATTR-CM score as compared to the rule-in cut-off of high-sensitivity troponin T.
Conclusions
The Mayo ATTR-CM score has a good performance in identifying patients with ATTR-CA, with also better discrimination power when compared to other scores and biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
- Health Sciences Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, Italy.
- Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
Zitieren
APA
Bonfioli, G. B., Tomasoni, D., Vergaro, G., Castiglione, V., Adamo, M., Fabiani, I., Loghin, V., Lombardi, C. M., Nicolai, A., Metra, M., Emdin, M., & Aimo, A. (2025). The Mayo ATTR-CM Score Versus Other Diagnostic Scores and Cardiac Biomarkers in Patients with Suspected Cardiac Amyloidosis. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3455
Vancouver
Bonfioli GB, Tomasoni D, Vergaro G, Castiglione V, Adamo M, Fabiani I, et al. The Mayo ATTR-CM Score Versus Other Diagnostic Scores and Cardiac Biomarkers in Patients with Suspected Cardiac Amyloidosis. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.3455
BibTeX
@article{Bonfioli2025,
author = {Bonfioli, Giovanni Battista and Tomasoni, Daniela and Vergaro, Giuseppe and Castiglione, Vincenzo and Adamo, Marianna and Fabiani, Iacopo and Loghin, Victor and Lombardi, Carlo Mario and Nicolai, Alessio and Metra, Marco and Emdin, Michele and Aimo, Alberto},
title = {The Mayo ATTR-CM Score Versus Other Diagnostic Scores and Cardiac Biomarkers in Patients with Suspected Cardiac Amyloidosis},
journal = {European Journal of Heart Failure},
year = {2025},
doi = {10.1002/ejhf.3455}
}
EUVIMED